Background. The management of patients with asymptomatic papillomavirus infection is still a controversial issue. Previous studies have demonstrated the potential of using immunomodulatory therapy in patients with latent form of HPV-infection.

OBJECTIVE

To optimize therapy in subjects with latent form of papillomavirus infection.

MATERIAL AND METHODS

Prospective randomized controlled trial included 66 patients infected by HPV. Patients of study group received 3 courses of recombinant IFN alpha-2b with antioxidants by 1 suppository per rectum in a dose of 3 000 000 IU at the bedtime for 10 days. Patients of comparative group remained under medical observation without pharmacological intervention. A qualitative change of HPV content was identified and a quantitative load of HPV was monitored after 4 weeks in patients of both groups.

RESULTS

Complete elimination of identified HPV genotypes has been found in 64.5% of patients in the study group, while in the comparison group only in 5.7% (p<0.001). The lack of qualitative changes in HPV content has been revealed in 68.6% of patients in the comparison group and in 12.9% of patients in the study group. The analysis of total viral load after treatment showed a reliable advantage of recombinant IFN alpha-2b: viral load reduced by 3.5 times in the study group, viral load did not change in the comparison group.

CONCLUSION

The study demonstrated a pronounced positive effect of examined drug in the treatment of papillomavirus infection latent forms. Course therapy with recombinant IFN alpha-2b combined with antioxidants allowed to achieve positive dynamics in 80% of patients, including complete HPV elimination in 64.5% and reduction of viral load by 3.5 times.